RT Journal Article
SR Electronic
T1 BCL11A intellectual developmental disorder: defining the clinical spectrum and genotype-phenotype correlations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.06.21262776
DO 10.1101/2021.09.06.21262776
A1 Peron, Angela
A1 D’Arco, Felice
A1 Aldinger, Kimberly A.
A1 Smith-Hicks, Constance
A1 Zweier, Christiane
A1 Gradek, Gyri A.
A1 Bradbury, Kimberley
A1 Accogli, Andrea
A1 Andersen, Erica F.
A1 Au, Ping Yee Billie
A1 Battini, Roberta
A1 Beleford, Daniah
A1 Bird, Lynne M.
A1 Bouman, Arjan
A1 Bruel, Ange-Line
A1 Busk, Øyvind Løvold
A1 Campeau, Philippe M.
A1 Capra, Valeria
A1 Carlston, Colleen
A1 Carmichael, Jenny
A1 Chassevent, Anna
A1 Clayton-Smith, Jill
A1 Bamshad, Michael J
A1 Earl, Dawn L.
A1 Faivre, Laurence
A1 Philippe, Christophe
A1 Ferrerira, Patrick
A1 Graul-Neumann, Luitgard
A1 Green, Mary J.
A1 Haffner, Darrah
A1 Haldipur, Parthiv
A1 Hanna, Suhair
A1 Houge, Gunnar
A1 Hurst, Jane
A1 Kraus, Cornelia
A1 Kristiansen, Birgit Elisabeth
A1 Lespinasse, James
A1 Low, Karen J.
A1 Lynch, Sally Ann
A1 Maia, Sofia
A1 Mao, Rong
A1 Marcinkute, Ruta
A1 Melver, Catherine
A1 McDonald, Kimberly
A1 Montgomery, Tara
A1 Morleo, Manuela
A1 Motter, Constance
A1 Openshaw, Amanda S.
A1 Palumbos, Janice Cox
A1 Parikh, Aditi Shah
A1 Person, Richard
A1 Desai, Megha
A1 Piard, Juliette
A1 Pfundt, Rolph
A1 Scala, Marcello
A1 Serey-Gaut, Margaux
A1 Slavotinek, Anne
A1 Suri, Mohnish
A1 Turner, Claire
A1 Tvrdik, Tatiana
A1 Weiss, Karin
A1 Wentzensen, Ingrid M.
A1 Zollino, Marcella
A1 ,
A1 ,
A1 ,
A1 de Vries, Bert B.A.
A1 Guillemot, Francois
A1 Dobyns, William B.
A1 Viskochil, David
A1 Dias, Cristina
YR 2021
UL http://medrxiv.org/content/early/2021/09/15/2021.09.06.21262776.abstract
AB Purpose Heterozygous variants in BCL11A underlie an intellectual developmental disorder with persistence of fetal hemoglobin (BCL11A-IDD, a.k.a. Dias-Logan syndrome). We sought to delineate the genotypic and phenotypic spectrum of BCL11A-IDD.Methods We performed an in-depth analysis of 42 patients with BCL11A-IDD ascertained through a collaborative network of clinical and research colleagues. We also reviewed 33 additional affected individuals previously reported in the literature or available through public repositories with clinical information.Results Molecular and clinical data analysis of 75 patients with BCL11A-IDD identified 60 unique variants (30 frameshift, 7 missense, 6 splice-site, 17 stop-gain) and 8 unique CNVs (microdeletions involving BCL11A only). We redefined the most frequent manifestations of the condition: intellectual disability, hypotonia, behavioral abnormalities, postnatal microcephaly and autism spectrum disorder. Two thirds of patients have brain MRI abnormalities, and we identified a recurrent posterior fossa phenotype of vermian hypoplasia and/or small brainstem. Truncating BCL11A variants, particularly those affecting the long (BCL11A-L) and extra-long (-XL) isoforms, sparing the short (-S) isoform, were associated with increased severity.Conclusions We expand the clinical delineation of BCL11A-IDD and identify a potential isoform-specific genotype-phenotype correlation. We show that BCL11A-IDD is associated with posterior fossa anomalies and highlight the differences between BCL11A-IDD and 2p16.1p15 microdeletion syndrome.Competing Interest StatementR.P., M.D. and I.M.W. are employees of GeneDx, Inc. a fee-for-service testing laboratory. M.J.B. is Chair of the Scientific Advisory Board of GeneDx. All the other authors declare no conflicts of interest.Funding StatementC.D. is supported by the Wellcome Trust [grant number 209568/Z/17/Z]. The BUILD Study is supported by the Wellcome Trust [grant number 209568/Z/17/Z], the NIHR UK Rare Genetic Disease Research Consortium and The Great Ormond Street Hospital NIHR Clinical Research Facility. A-L.B.'s work was supported by grants from the Regional Council of Burgundy (Plan d'Actions Régional pour l'Innovation-PARI) and the fonds européen de développement regional (FEDER). B.B.A.d.V's work was financially supported by grants from the Dutch Organization for Health Research and Development (ZON-MW grants 917-86-319 and 912-12-109). D.B's work was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA210561, Akhurst PI (DTB). M.J.B. and the UW-CMG are supported by NHGRI and NHLBI grants UM1 HG006493 and U24 HG008956, by the Office of the Director, NIH under Award Number S10OD021553. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the ethics committee of the following institutions: Deciphering Developmental Disorders Study: Cambridge South REC reference 10/H0305/83, and Republic of Ireland REC GEN/284/12; The 100,000 Genomes Project: Cambridge South REC 14/EE/1112; The BUILD Study: London - Camden & Kings Cross REC 17/LO/0981; Seattle Children's Hospital IRB study #13291; Translational Genomics Research Institute: WCG IRB Protocol #20120789; Ethical review board of Friedrich-Alexander-University, Erlangen-Nürnberg, Germany; University of California San Diego: IRB protocol #101103; Johns Hopkins Medicine IRB protocol IRB00214093. For clinically ascertained individuals exempt from IRB, patient/guardian consent was given for publication of de-identified data and the appropriate institutional forms have been archived. Fetal samples: The HDBR has ethical approval (REC 18/NE/0290).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesClinical and molecular data included in this study will be made publicly available at www.bcl11agene.com on peer-reviewed publication. Genetic analyses: for access to the retrospectively performed analyses, please contact the authors who will refer to the appropriate center (data availability is subject to each individual study's ethics and consent).